Rchr
J-GLOBAL ID：201801010879035264
Update date: Oct. 22, 2024
Kawamoto Yasuyuki
カワモト ヤスユキ | Kawamoto Yasuyuki
Affiliation and department：
Research field (2)：
Gastroenterology
, Tumor diagnostics and therapeutics
Research theme for competitive and other funds (3)：
- 2024 - 2027 Effect of tumor microbiome on tumor immune evasion in pancreatic cancer
- 2020 - 2024 An investigator-initiated phase II trial of niraparib for patients with BRCA-mutated unresectable/recurrent biliary tract, pancreatic and other gastrointestinal cancer
- 2019 - 2021 Analysis of the pancreatic cancer microbiome using endoscopic ultrasound-guided fine-needle aspiration derived samples
Papers (119)：
-
Shuichi Mitsunaga, Masafumi Ikeda, Shogo Nomura, Chigusa Morizane, Akiko Todaka, Naoto Yamamoto, Ken Kamata, Hiroo Yanagibashi, Nobumasa Mizuno, Yasuyuki Kawamoto, et al. 5-Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S-1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer (JCOG1202A1). Journal of hepato-biliary-pancreatic sciences. 2024
-
Yoshiyuki Yamamoto, Hiroki Yukami, Tatsuro Yamaguchi, Hisatsugu Ohori, Sachiko Nagasu, Yoshinori Kagawa, Naotoshi Sugimoto, Hiromichi Sonoda, Kentaro Yamazaki, Atsuo Takashima, et al. Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study. International journal of clinical oncology. 2024
-
Kentaro Sudo, Yoshiaki Nakamura, Makoto Ueno, Masayuki Furukawa, Nobumasa Mizuno, Yasuyuki Kawamoto, Naohiro Okano, Kumiko Umemoto, Akinori Asagi, Masato Ozaka, et al. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer. British journal of cancer. 2024. 131. 7. 1237-1245
-
Hiroshi Nakatsumi, Yoshito Komatsu, Kazuaki Harada, Yasuyuki Kawamoto, Satoshi Yuki, Kentaro Sawada, Atsushi Ishiguro, Susumu Sogabe, Takayuki Ando, Yusuke Sasaki, et al. A multicenter, prospective, phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti-EGFR antibody: HGCSG1801. International journal of cancer. 2024
-
Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto, Yoshito Komatsu, Makoto Ueno, Satoshi Kobayashi, Masafumi Ikeda, Mitsuhito Sasaki, Junji Furuse, Naohiro Okano, et al. Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024. 42. 27. JCO2302010-3217
ｍore...
MISC (106)：
-
野路 武寛, 永山 稔, 今井 浩二, 川本 泰之, 桒谷 将城, 今村 将史, 岡村 圭佑, 木村 康利, 平野 聡. 当初非切除とした胆道癌に対する集学的治療後の外科切除(Conversion surgery)の成績 : 北海道多施設共同研究-Conversion surgery for initially unresectable biliary malignancies : a multicenter retrospective cohort study. 北海道外科雑誌 = The Hokkaido journal of surgery / 北海道外科雑誌編集委員会 編. 2021. 66. 1. 42-46
-
野路武寛, 松井あや, 田中公貴, 中西喜嗣, 渡邉祐介, 浅野賢道, 海老原裕磨, 倉島庸, 中村透, 村上壮一, et al. 再発胆道癌に対する積極的外科切除の成績. 日本消化器外科学会雑誌(Web). 2021. 54. Supplement2
-
小泉富基, 加藤徳雄, 中村透, 川本泰之, 高尾聖心, 阿保大介, 清水伸一, 清水伸一, 青山英史. Conversion surgery for locally advanced unresectable pancreatic cancer treated with proton beam therapy combined with S-1 chemotherapy: a case report and literature review. 臨床放射線. 2021. 66. 8
-
T. Kawakami, K. Yamazaki, H. Go, T. Masuishi, Y. Kawamoto, K. Kato, R. Kumanishi, K. Sawada, H. Shirasu, S. Yuki, et al. The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC): Updated analysis. ANNALS OF ONCOLOGY. 2020. 31. S433-S434
-
平岡 弓枝, 中村 能章, 田辺 記子, 平田 真, 川本 泰之, 池田 公史, 坂東 英明, 江崎 泰斗, 上野 誠, 洞澤 智至, et al. 進行消化器がんを対象としたGOZILA studyにおけるcirculating tumor DNA(ctDNA)解析による二次的所見(SF)に関する調査. 日本遺伝カウンセリング学会誌. 2020. 41. 2. 78-78
ｍore...
Education (2)：
- 2008 - 2012 Hokkaido University Graduate School of Medicine
- 1998 - 2004 Hokkaido University School of Medicine
Professional career (1)：
- Medical Doctor (Hokkaido University)
Return to Previous Page
